Hyku Funding & Investors

Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins. The Hyku platform identifies molecules that covalently bind non-cysteine amino acids to aid in the creation of innovative medicines that can address present issues with a variety of disease targets, such as selectivity, druggability, and resistance.